Replies to post #269771 on Avid Bioservices Inc (CDMO)

[Protector]

entdoc, I think there was a companion test with Opdivo for PD-L1 responders detection.

I am sure BMY is going to be stratifying responders and non-responders on the percentage of PD-L1, yada.

If you combine with bavituximab that test may not be good anymore because the # of responders should increase. The test however would continue to yield the max 30% responders.

Maybe the test will be a filter for who can get Opdivo alone (30%) or Opdivo+Bavi (60-70%). However, that would not be a good development because the 30% would not get the other Bavi advantages of milding side effects by kicking on the immune system and they would not benefit the anti-relapse properties of Bavituximab (and Fx-gamma binding).